Neuren (NEU) - ASX Announcement

31 May 2017

Neuren announces grant of two new patents for trofinetide to 2032

Melbourne, Australia, 31 May 2017: Neuren Pharmaceuticals (ASX: NEU) today announced the approved grant of two new patents in the United States and Europe concerning the use of trofinetide to treat autism spectrum disorders. When issued each patent will expire in January 2032.

The US Patent and Trademark Office has provided a Notice of Allowance for a new patent covering the use of trofinetide to treat Fragile X syndrome. A similar patent covering its use in Rett syndrome was issued to Neuren in December 2015.

The European Patent Office has issued a notice of Intention to Grant a new patent concerning the use of trofinetide to treat autism spectrum disorders, which include Rett syndrome and Fragile X syndrome.

Trofinetide is covered by issued composition of matter patents in the United States and in Europe, which expire in 2022, with the potential to extend to 2027. The new patents provide additional protection out to 2032. Neuren also has a patent granted in Australia concerning the use of trofinetide to treat autism spectrum disorders and similar patent applications pending in Japan, Canada, Brazil and Israel.

In addition, Neuren has orphan drug designation in the United States and in the European Union for both Rett syndrome and Fragile X syndrome. This provides a market exclusivity period following marketing authorization of 7 years in the United States and 10 years in the European Union.

For more information, please contact:
Jon Pilcher, CFO & Company Secretary: jipilcher@neurenpharma.com ; +61 438 422 271

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for neurodevelopmental disorders, neurodegenerative diseases and acute brain injury. Neuren presently has a clinical stage molecule, trofinetide in Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development.

About trofinetide

Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia, correcting deficits in synaptic function and regulating oxidative stress response. Trofinetide is being developed both in intravenous and oral formulations for a range of acute and chronic conditions. The most advanced program is for Rett syndrome, supported by Rettsyndrome.org. Both the Rett syndrome and Fragile X
syndrome programs have been granted Fast Track designation by the US Food and Drug Administration (FDA) and have orphan drug designation in both the United States and the European Union.

Forward-looking Statements
This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.